Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.640
+0.2302.44%
Volume:137.30M
Turnover:1.33B
Market Cap:111.07B
PE:24.32
High:9.980
Open:9.505
Low:9.430
Close:9.410
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.04
T/O Rate:1.19%
Dividend:0.29
Dividend Rate:3.01%
EPS(LYR):0.396
ROE:20.90%
ROA:10.70%
PB:2.53
PE(LYR):24.32
PS:3.04

Loading ...

Alphamab Oncology Says China NMPA Accepts Anbenitamab NDA for First-Line HER2+ Advanced Breast Cancer

Reuters
·
Aug 18

CSPC Pharmaceutical - Kn026 and Hb1801 Combination Previously Granted Breakthrough Therapy Designation by Nmpa

THOMSON REUTERS
·
Aug 18

CSPC Pharmaceutical - Nda Indication: First-Line Treatment of Unresectable or Metastatic Her2-Positive Breast Cancer

THOMSON REUTERS
·
Aug 18

CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue

Reuters
·
Aug 17

CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan

Reuters
·
Aug 17

Movement Alert|CSPC PHARMA Rises 3.22% in Regular Trading, Innovative Pharma Sector Strengthens as AstraZeneca Payments Confirmed

Market Focus
·
Aug 17

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 13

Earning Preview: CSPC PHARMA Q2 revenue expected to increase by 25.43%, institutional views are bullish

Earnings Agent
·
Aug 13

Movement Alert|CSPC PHARMA Rises 3.57% in Regular Trading, AstraZeneca siRNA Collaboration $30 Million Upfront Payment Received

Market Focus
·
Aug 13

CSPC Pharmaceutical Changes Trustee for 2018 Share Award Scheme to BOCI Trustee Hong Kong

Reuters
·
Aug 12

CSPC Pharmaceutical Group Announces Change in Trustee for 2018 Share Award Scheme

Stock News
·
Aug 12

CSPC Pharmaceutical Receives USD 30 Million Upfront Payment from AstraZeneca Under siRNA Pact

Reuters
·
Aug 12

CSPC Pharmaceutical - Receives US$30 Mln Upfront Payment from AstraZeneca on Aug 12 2026 Under Collaboration Agreement

THOMSON REUTERS
·
Aug 12

CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus

MT Newswires Live
·
Aug 12

CSPC Pharma's SYS 6063 Trial for Lupus Clears First Site in China

Stock News
·
Aug 11

CSPC Pharmaceutical - Pharma Initiates Phase I Trial of Sys6063 for Relapsed, Refractory Sle in China

THOMSON REUTERS
·
Aug 11

Movement Alert|CSPC PHARMA Rises 3.19% in Regular Trading, Monkeypox mRNA Vaccine Receives FDA Clinical Trial Approval

Market Focus
·
Aug 11

CSPC Pharmaceutical's Mpox Vaccine Candidate Gets Trial Approval from US FDA

MT Newswires Live
·
Aug 10

CSPC Pharma Sets 20 Aug 2026 Board Meeting to Approve 1H 2026 Interim Results

Bulletin Express
·
Aug 10

CSPC Pharma (01093) Receives FDA Clearance for US Clinical Trial of Monkeypox mRNA Vaccine

Stock News
·
Aug 10